Synonyms: (S)-3-Chloro-7-(2-(hydroxymethyl)morpholino)-2-methyl-5-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridine-6-carbonitrile; PF 06869206; PF06869206
Molecular Formula: C15H14ClF3N4O2
Molecular Weight: 374.75
Linear Structural Formula: C15H14ClF3N4O2
Purity: >=98% (HPLC)
Storage: room temp
Application: PF-06869206 has been used to selectively inhibit the activity of sodium-phosphate cotransporter 2a (NaPi2a).
Biochem Physiol Actions: PF-06869206 may be used to treat patients with mineral and hormonal derangements linked with increased cardiovascular risk in chronic kidney disease. This drug might also improve urinary phosphate excretion. PF-06869206 has an ability to decrease phosphate uptake in human embryonic kidney (HEK) cells transfected with mouse or rat renal sodium-dependent phosphate transporter genes (Npt2a).
Legal Information: Sold for research purposes under agreement from Pfizer Inc